Multi-Antigen Diagnostic Tests Cancellation
Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEINDUSTRIAL BASED MANUFACTURING AND SUPPLY CHAIN (IBMSC)Washington, DC, 20024, USA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Original Source

https://sam.gov/workspace/contract/opp/4777728c37b8427292a4220d047455b9/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response, has issued a Special Notice regarding the cancellation of the Combined Synopsis/Solicitation Notice ID 75A50424R00006 for Multi-Antigen Diagnostic Tests. This cancellation indicates that the procurement for these in-vitro diagnostic substances, which are critical for various health assessments, will no longer proceed as initially planned. The opportunity was set aside for small businesses under the SBA guidelines, emphasizing the government's commitment to supporting small enterprises in the healthcare sector. For further inquiries, interested parties can contact Rachelle Colon-Serna at rachelle.colon-serna@hhs.gov.

    Point(s) of Contact
    Rachelle Colon-Serna
    rachelle.colon-serna@hhs.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Multi-Antigen Diagnostic Tests Cancellation
    Currently viewing
    Special Notice
    Similar Opportunities
    COVID 19 Tests
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response, is seeking procurement for COVID-19 tests. The opportunity involves the acquisition of in vitro diagnostic substances, reagents, test kits, and sets, with a focus on ensuring compliance with the Trade Agreements Act (TAA). This procurement is critical for enhancing the nation's testing capabilities in response to the ongoing pandemic. Interested vendors can reach out to Junli Collins at junli.collins@hhs.gov or Judy Williams at judy.williams2@hhs.gov for further details, as outlined in the attached justification document.
    BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking qualified contractors to support the development of vaccine medical countermeasures for pandemic influenza preparedness and response. The objective of this Sources Sought Notice (SSN) is to refine requirements and establish long-term partnerships with contractors capable of producing vaccines, antigens, and adjuvants necessary for pandemic preparedness and public health emergencies. This initiative is critical for enhancing the U.S. response to influenza viruses with pandemic potential and ensuring rapid regulatory decisions and manufacturing readiness. Interested parties must submit evidence of eligibility, capabilities statements, and requests to participate by email to Laura Saddison at Laura.Saddison@hhs.gov by 3:00 pm EST on December 19, 2025. This SSN/RFI is for information and planning purposes only and does not constitute a solicitation.
    Notice of Intent to Sole Source Modification of Contract to Quest Diagnostics, Inc.
    Buyer not available
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), intends to negotiate a non-competitive modification to an existing contract with Quest Diagnostics, Inc. This modification aims to expand the scope of the contract to include access to de-identified antibody results from previously tested specimens, focusing on individuals with immunocompromising conditions as part of the CDC's Multistate Assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) Study. The contract modification is crucial for estimating the prevalence of SARS-CoV-2 infections and vaccinations across various demographics and geographic locations, utilizing existing data rather than incurring additional costs for new specimen collection. Interested parties may submit responses to this notice within 15 days to the primary contact, Liz Cole-Greenblatt, at qst7@cdc.gov, although the government retains discretion over whether to pursue competitive procurement.
    Assay Development for Superior Understanding of Response and Efficacy (ASSURE)
    Buyer not available
    The Department of Health and Human Services, through the Office of Assistant Secretary for Preparedness and Response (ASPR BARDA), is soliciting proposals for the ASSURE program, which focuses on the development of innovative assays to evaluate immune responses to infections and vaccinations. The primary objective is to create multiplexed, high-throughput, scalable, and sample-sparing assays that can assess immune status in response to chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and other emerging infectious diseases. Approximately $8 million is available for four to five awards, with proposals evaluated based on technical approach, relevant experience, and cost reasonableness. Interested parties must submit an abstract by December 18, 2025, and can contact Rebecca Harmon at rebecca.harmon@ati.org or 843.760.3358 for further information.
    Notice of Intent - Xpert Xpress CoV-2/Flu/RSV plus
    Buyer not available
    The Indian Health Service, specifically the Navajo Area Indian Health Service, intends to negotiate a sole-source contract with Cepheid Inc. for the procurement of Xpert Xpress CoV-2/Flu/RSV Plus test kits. This procurement is aimed at ensuring the availability of diagnostic tests that are compatible with the GeneXpert instrument, which is critical for effective health management in the region. The contract will cover a base period from January 1, 2026, to December 31, 2026, with four additional option periods extending through December 31, 2030. Interested vendors who believe they can meet the requirements are invited to submit a capability statement by 10:00 AM (MST) on December 11, 2025, to Dallas Begay at dallas.begay@ihs.gov.
    GMP Manufacturing of CDC FluSC2 Multiplex EUA Kit
    Buyer not available
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), has awarded a contract for the GMP manufacturing of the CDC FluSC2 Multiplex EUA Kit to Biosearch Technologies, Inc. This contract, valued at $399,993, entails the production of 1,020 vials of oligonucleotide primers and probes, adhering to Good Manufacturing Practices (GMP) as defined under 21 CFR 820, with a required delivery date of September 25, 2023. The specific internal BHQnova quencher design of the probes is critical for the diagnostic assay, which has received Emergency Use Authorization (EUA) from the FDA, and no other suppliers have been identified that can meet these stringent requirements. For further inquiries, interested parties may contact Mark Draluck at syq1@cdc.gov or Devin Barich at uca9@cdc.gov.
    Hologic Covid Testing Supplies
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is seeking to procure Hologic COVID-19 testing supplies for the Tidewater Contracting Division. This sole source acquisition, valued at $1,697,962.00, is essential for maintaining the functionality of existing analyzers at NH Jacksonville, as Hologic is the only vendor capable of providing the necessary compatible assays and reagents. The procurement is critical for ongoing COVID-19 testing efforts, and market research has confirmed that no substitute items are available, thus justifying the sole source approach. Interested parties can reach out to Jessica Horst at jessica.l.horst5.civ@health.mil or Annette Jackson at annette.d.jackson2.civ@health.mil for further information.
    66--TEST KIT, HP
    Buyer not available
    The Department of Defense, specifically the Department of the Navy, is seeking proposals for the manufacture of three units of a Test Kit HP, identified by NSN 7H-6685-017081470-X5. The procurement requires delivery of these kits to designated distribution centers in Pennsylvania and California within 140 days after contract award, emphasizing the importance of timely fulfillment for operational readiness. This opportunity is set aside for small businesses under the Total Small Business Set-Aside program, and interested parties must contact Michael B. Duffy at 564-230-2254 or via email at MICHAEL.B.DUFFY2@NAVY.MIL to obtain the solicitation number N00104-26-Q-BE38 and further details. Proposals must adhere to the requirements outlined in the solicitation, and government source inspection will be required.
    BIO RAD HbA1C
    Buyer not available
    The Department of Veterans Affairs is issuing a Special Notice for a sole source procurement of BIO RAD HbA1C, which falls under the In-Vitro Diagnostic Substance Manufacturing category. This procurement aims to acquire essential diagnostic substances, specifically reagents and test kits, that are critical for monitoring and managing diabetes among veterans. The goods will be delivered to Cleveland, Ohio, and are vital for ensuring accurate and timely health assessments within the VA healthcare system. Interested vendors can reach out to Rachelle Hamer at rachelle.hamer@va.gov or call 216-447-8300 for further details regarding this opportunity.
    MCSC PDSS Support Services - CANCELLATION
    Buyer not available
    The Department of Defense, specifically the Department of the Navy, has announced the cancellation of Solicitation M6785424R7603 for Post Deployment System Support (PDSS) services for the Program Manager Logistics Integrated Information Solutions – Marine Corps (LI2S-MC). The cancellation is due to a latent ambiguity in the solicitation's requirements and changes in government needs, which necessitate a revision to ensure clarity and promote fair competition among potential offerors. A revised solicitation is expected to be issued within the next 120 days, and interested parties are encouraged to monitor SAM.gov for updates. For inquiries regarding this cancellation, please contact Ms. Renée S. Stahl at renee.stahl@usmc.mil.